Academic
Publications
Screening and Prostate-Cancer Mortality in a Randomized European Study

Screening and Prostate-Cancer Mortality in a Randomized European Study,Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Teuvo L. J. Tammela,Stefano

Screening and Prostate-Cancer Mortality in a Randomized European Study   (Citations: 146)
BibTex | RIS | RefWorks Download
Fritz H. Schröder, Jonas Hugosson, Monique J. Roobol, Teuvo L. J. Tammela, Stefano Ciatto, Vera Nelen, Maciej Kwiatkowski, Marcos Lujan, Hans Lilja, Marco Zappa, Louis J. Denis, Franz Reckerhttp://academic.research.microsoft.com/io.ashx?type=5&id=13346390&selfId1=0&selfId2=0&maxNumber=12&query=
In the screening group, 82% of men accepted at least one offer of screening. During a median follow-up of 9 years, the cumulative incidence of prostate cancer was 8.2% in the screening group and 4.8% in the control group. The rate ratio for death from prostate cancer in the screening group, as compared with the control group, was 0.80 (95% confidence interval (CI), 0.65 to 0.98; adjusted P = 0.04). The absolute risk difference was 0.71 death per 1000 men. This means that 1410 men would need to be screened and 48 additional cases of prostate cancer would need to be treated to prevent one death from prostate cancer. The analysis of men who were actually screened during the first round (excluding subjects with noncompliance) provided a rate ratio for death from prostate cancer of 0.73 (95% CI, 0.56 to 0.90). Conclusions PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis. (Current Controlled Trials number, ISRCTN49127736.)
Published in 2010.
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: